Page last updated: 2024-08-16

rofecoxib and Cardiovascular Diseases

rofecoxib has been researched along with Cardiovascular Diseases in 147 studies

Research

Studies (147)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	137 (93.20)	29.6817
2010's	9 (6.12)	24.3611
2020's	1 (0.68)	2.80

Authors

Authors	Studies
Kesselheim, AS; Lee, TT; Solomon, DH	1
Moore, N	1
Hirota, T; Miyajima, A; Muto, T; Okamoto, M	1
Evans, G; McIntyre, WF	1
Anwar, A; Anwar, IJ; Delafontaine, P	1
Madigan, D; Sobel, M; Wang, W	1
Conforti, A; Leone, R; Montanaro, N; Moretti, U; Motola, D; Vaccheri, A; Vargiu, A; Velo, G	1
Dejaco, C; Jaksch, W; Schirmer, M	1
Leufkens, HG; Setakis, E; van Staa, TP	1
Baron, JA; Bresalier, RS; Demets, DL; Iverson, ER; Lanas, A; Morton, DG; Riddell, R; Sandler, RS	1
Barry, WT; Bottone, FG	1
Aiyar, N; Behm, DJ; Bentley, RG; Coatney, RW; Doe, CP; Eybye, ME; Maniscalco, K; Olzinski, AR; Westfall, TD; Willette, RN; Zhao, S	1
Simon, LS; White, WB	1
Arbogast, PG; Castellsague, J; Chung, CP; Daugherty, JR; García-Rodríguez, LA; Murray, KT; Ray, WA; Stein, CM; Varas-Lorenzo, C	1
Hsiao, FY; Huang, WF; Tsai, YW	1
Ai, D; Chiamvimonvat, N; Hammock, BD; Li, N; Liu, JY; Qiu, H; Yang, J; Zhu, Y	1
Egilman, DS; Konstam, MA; Krumholz, HM; Madigan, D; Ross, JS	1
Bäck, M; Ingelsson, E; Yin, L	1
Avorn, J; Furberg, CD; Madigan, D; Mayer, JW; Sigelman, DW	1
Brozek, J; Gajewski, P; Jaeschke, R	1
Burke, TA; Henderson, SC; von Allmen, H; Whelton, A; Zhao, SZ	1
Sonnenblick, EH	1
Bucher, M; Dreher, F; Höcherl, K; Kurtz, A	1
Harley, C; Wagner, S	1
Dulai, GS; Gralnek, IM; Spiegel, BM; Targownik, L	1
Burnier, M; Chiolero, A; Maillard, MP	1
Dixon, ME; Geba, GP; Johansson, G; Lisse, JR; Mollen, AJ; Perlman, M; Polis, AB; Schechtman, J; Shoemaker, JR; Skalky, CS	1
Konstam, MA	1
Cleland, LG; James, MJ	1
Aw, J; Haas, S; Krum, H; Liew, D	1
Fitzgerald, GA	1
Adams, D	1
Eikelboom, JW; Hankey, GJ; Langton, PE	1
Egan, KM; Fitzgerald, GA; Fries, S; Koller, B; Lawson, JA; Rader, DJ; Smyth, EM	1
Kondro, W	1
Frantz, S	1
Bijlsma, JW	1
Zierenberg, O	1
Lenzer, J	1
Simon, LS; Strand, V	1
Håkansson, J; Rosenberg, P	1
Davies, NM; Jamali, F	1
Couzin, J	3
Oakley, G	1
Juhlin, R	1
Scheen, AJ	1
Kim, PS; Reicin, AS	1
Villalba, L; Witter, J	1
Wolfe, MM	1
Hedner, T; Melander, A	1
Hansen, PR	1
Callréus, T	1
Meyer, CH	1
Berenbaum, F	1
Wardle, EN	1
Kamen, B; Kieran, M	1
Senior, K	1
Baron, JA; Bolognese, JA; Bresalier, RS; Horgan, K; Konstam, MA; Lanas, A; Lines, C; Morton, D; Oxenius, B; Quan, H; Riddell, R; Sandler, RS	1
Furberg, CD; Psaty, BM	1
Drazen, JM	1
Giannitsis, E	1
Arellano, FM	1
Weinberg, JM	1
Graham, DJ; Grosser, SC; Nourjah, P; Rawson, NS	1
Smith, ER	1
Aldington, S; Beasley, R; Caldwell, B; Shirtcliffe, P; Weatherall, M	1
Jerie, P	1
Laible, B	1
Okie, S	1
Eisenberg, RS	1
Evensen, S; Slørdal, L; Spigset, O	1
Maloney, DM	1
Ashton, J; Harrison-Woolrych, M; Herbison, P; McLean, R; Slattery, J	1
Bolten, WW; Reiter, S	1
Fortun, PJ; Hawkey, CJ	1
Burnier, M	1
de Boer, A; Florentinus, SR; Heerdink, ER; Leufkens, HG; van Dijk, L	1
Braunstein, N; Polis, A	1
Brophy, JM	1
Khamsi, R	1
Manthous, CA	1
Daikh, DI	1
Messerli, FH; Sichrovsky, T	1
Frazier, KC	1
Araujo, LF; Fernandes, Jde L; Serrano Júnior, CV; Soeiro, Ade M	1
Barnett, EM; Bobadilla, RV; Randels, CL	1
Chowienczyk, P; Kirkham, B; Wong, M	1
Rainsford, KD	1
Wadman, M	2
de Champlain, J; Laplante, MA; Wu, R	1
Curfman, GD; Drazen, JM; Morrissey, S	1
Bombardier, C; Burgos-Vargas, R; Davis, B; Day, R; Ferraz, MB; Hawkey, CJ; Hochberg, MC; Kvien, TK; Laine, L; Schnitzer, TJ; Weaver, A	1
Guo, ZR	1
Hsiao, FY; Huang, WF; Shih, YT; Tsai, YW; Wen, YW	1
Dogné, JM; Hanson, J; Pratico, D; Supuran, C	1
Geisslinger, G; Tegeder, I	1
Sooriakumaran, P	1
Nelson, NJ	1
van der Veen, WJ; van der Werf, GT	1
Hawker, GA; Katz, JN; Solomon, DH	1
Nissen, SE	1
Barner, JC; Busti, AJ; Lawson, KA; Motsko, SP; Rascati, KL; Wilson, JP; Worchel, J	1
Furberg, CD	1
Armstrong, D	1
Hind, C; Singh, M; Williams, D	1
Henry, D; McGettigan, P	1
Marwali, MR; Mehta, JL	1
Mühlbauer, B; Timm, J	1
Andersohn, F; Garbe, E; Pigeot, I; Scharnetzky, E; Schill, W	1
Häussler, B; Höer, A	1
Bennett, K; Feely, J; Teeling, M; Usher, C	1
Deray, G; Montalescot, G; Sibilia, J	1
Deray, G; Héloire, F; Valat, JP	2
Schwarz, ER; Zarraga, IG	1
Egilman, DS; Krumholz, HM; Presler, AH; Ross, JS	1
Jugdutt, BI	1
Ashworth, AJ	1
Tabrizchi, R	1
Amouretti, M; Bégaud, B; Bénichou, J; Blin, P; Depont, F; Droz, C; Fourrier, A; Merlière, Y; Moore, N; Moride, Y; Sturkenboom, M; Velo, GP	1
Hellstrom, HR	1
Salzberg, DJ; Weir, MR	1
Dunn, JA; Duvvuri, R; Iveson, C; Julier, P; Kerr, DJ; Langman, MJ; McConkey, CC; Midgley, RS; Smith, JL; Stanley, A; Stokes, JC	1
Badimon, L; Martínez-González, J	1
Avorn, J	1
Arlès, F; Brondex, A; Cornily, JC; Godon, P; Mansourati, J; Quiniou, G; Saraux, A; Vinsonneau, U	1
Chen, C; Erkens, JA; Herings, RM; Sukel, MP; van der Linden, MW	1
Mayer, TV	1
Bombardier, C; Burgos-Vargas, R; Davis, B; Day, R; Ferraz, MB; Hawkey, CJ; Hochberg, MC; Kvien, TK; Laine, L; Reicin, A; Schnitzer, TJ; Shapiro, D	1
Stienburg, KL	1
García Rodríguez, LA; Patrignani, P; Patrono, C	1
Gotlieb, D	1
FitzGerald, GA; Patrono, C	1
Comarow, A	1
Barr, E; Gertz, BJ; Konstam, MA; Reicin, A; Shapiro, D; Sperling, RS; Weir, MR	1
Barr, E; Reicin, AS; Shapiro, D; Sperling, RS; Yu, Q	1
Sharma, RA	1

Reviews

37 review(s) available for rofecoxib and Cardiovascular Diseases

Article	Year
Coronary Risks Associated with Diclofenac and Other NSAIDs: An Update. Drug safety, 2020, Volume: 43, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiotoxicity; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Diclofenac; Humans; Lactones; Meta-Analysis as Topic; Myocardial Infarction; Risk Factors; Stroke; Sulfones	2020
Elevation of cardiovascular risk by non-steroidal anti-inflammatory drugs. Trends in cardiovascular medicine, 2015, Volume: 25, Issue:8 Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Case-Control Studies; Cyclooxygenase 1; Cyclooxygenase 2; Female; Follow-Up Studies; Homeostasis; Humans; Lactones; Male; Middle Aged; Naproxen; Prevalence; Randomized Controlled Trials as Topic; Risk Assessment; Sulfones	2015
4 years after withdrawal of rofecoxib: where do we stand today? Rheumatology international, 2008, Volume: 28, Issue:12 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Contraindications; Cyclooxygenase 2 Inhibitors; Drug and Narcotic Control; Drug Approval; Drug Therapy, Combination; Europe; Gastrointestinal Hemorrhage; Humans; Lactones; Proton Pump Inhibitors; Rheumatic Diseases; Risk; Sulfones; United States	2008
COX-2 selective inhibitors and heart health. Postgraduate medicine, 2005, Volume: 117, Issue:1 Suppl Topics: Adult; Cardiovascular Diseases; Celecoxib; Child; Cyclooxygenase 2 Inhibitors; Humans; Hypertension; Isoxazoles; Lactones; Meta-Analysis as Topic; Prospective Studies; Pyrazoles; Randomized Controlled Trials as Topic; Sulfonamides; Sulfones	2005
Differences between COX-2-specific inhibitors: clinical and economic implications. The American journal of managed care, 2002, Volume: 8, Issue:15 Suppl Topics: Aged; Blood Pressure; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Costs; Female; Humans; Isoenzymes; Lactones; Male; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Risk Factors; Sulfonamides; Sulfones; United States	2002
The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis. Annals of internal medicine, 2003, May-20, Volume: 138, Issue:10 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celecoxib; Chronic Disease; Cost-Benefit Analysis; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Decision Support Techniques; Humans; Isoenzymes; Lactones; Membrane Proteins; Osteoarthritis; Peptic Ulcer; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Quality-Adjusted Life Years; Recurrence; Risk Factors; Sensitivity and Specificity; Sulfonamides; Sulfones	2003
Cardiovascular hazard of selective COX-2 inhibitors: myth or reality? Expert opinion on drug safety, 2002, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Cardiovascular Diseases; Celecoxib; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Humans; Lactones; Osteoarthritis; Pyrazoles; Risk Factors; Sulfonamides; Sulfones	2002
Cardiovascular effects of selective cyclooxygenase-2 inhibitors. Expert review of cardiovascular therapy, 2004, Volume: 2, Issue:2 Topics: Cardiotonic Agents; Cardiovascular Diseases; Cardiovascular System; Celecoxib; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Dinoprostone; Disease Progression; Epoprostenol; Humans; Lactones; Pyrazoles; Sulfonamides; Sulfones	2004
[Withdrawal of rofecoxib (Vioxx): what about cardiovascular safety of COX-2 selective non-steroidal anti-inflammatory drugs?]. Revue medicale de Liege, 2004, Volume: 59, Issue:10 Topics: Cardiovascular Diseases; Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Isoenzymes; Lactones; Membrane Proteins; Product Surveillance, Postmarketing; Prostaglandin-Endoperoxide Synthases; Sulfones	2004
Rationale for testing the cardiovascular risk for patients with COX-2 inhibitors on the basis of biomarker NT-proBNP. Clinical laboratory, 2005, Volume: 51, Issue:1-2 Topics: Aged; Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Biomarkers; Cardiovascular Diseases; Clinical Medicine; Contraindications; Cyclooxygenase Inhibitors; Humans; Lactones; Natriuretic Peptide, Brain; Nerve Tissue Proteins; Osteoarthritis; Peptide Fragments; Risk Assessment; Sulfones	2005
[COX-2 inhibitors--one step forward and two steps back]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2005, Apr-07, Volume: 125, Issue:7 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Gastrointestinal Diseases; Humans; Lactones; Pyrazoles; Risk Factors; Sulfonamides; Sulfones	2005
Life after Vioxx: the clinical implications. Hospital medicine (London, England : 1998), 2005, Volume: 66, Issue:5 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Gastrointestinal Diseases; Humans; Lactones; Risk Assessment; Risk Factors; Sulfones	2005
The safety of rofecoxib. Expert opinion on drug safety, 2005, Volume: 4, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Cardiovascular Diseases; Case-Control Studies; Epidemiologic Studies; Kidney; Lactones; Product Labeling; Product Surveillance, Postmarketing; Risk Factors; Safety; Sulfones; Thromboembolism	2005
Does the pro-hypertensive effect of cyclooxygenase-2 inhibitors account for the increased risk in cardiovascular disease? The American journal of cardiology, 2005, Sep-15, Volume: 96, Issue:6 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Humans; Lactones; Pyrazoles; Randomized Controlled Trials as Topic; Risk Factors; Sulfonamides; Sulfones	2005
[Cardiovascular events: a class effect by COX-2 inhibitors]. Arquivos brasileiros de cardiologia, 2005, Volume: 85, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Humans; Lactones; Product Surveillance, Postmarketing; Pyrazoles; Risk Assessment; Sulfonamides; Sulfones	2005
COX-2 inhibitors and the heart: putting risk in perspective. Advance for nurse practitioners, 2005, Volume: 13, Issue:11 Topics: Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Clinical Trials as Topic; Cyclooxygenase 2 Inhibitors; Humans; Isoxazoles; Lactones; Patient Selection; Product Surveillance, Postmarketing; Risk Assessment; Risk Factors; Stomach Ulcer; Sulfonamides; Sulfones; United States; United States Food and Drug Administration	2005
Cardiovascular issues of COX-2 inhibitors and NSAIDs. Australian family physician, 2005, Volume: 34, Issue:11 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Clinical Protocols; Cyclooxygenase 2 Inhibitors; Humans; Hypertension; Lactones; Renal Insufficiency; Risk Assessment; Sulfones	2005
Introduction - The coxib controversies. Inflammopharmacology, 2005, Volume: 13, Issue:4 Topics: Animals; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Humans; Lactones; Sulfones	2005
[Innovation of anti-inflammatory drugs--inhibition of cyclooxygenases]. Yao xue xue bao = Acta pharmaceutica Sinica, 2005, Volume: 40, Issue:11 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Epoprostenol; Humans; Lactones; Pyrazoles; Sulfonamides; Sulfones; Thromboxane A2	2005
Coxibs and cardiovascular side-effects: from light to shadow. Current pharmaceutical design, 2006, Volume: 12, Issue:8 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Epoprostenol; Humans; Isoxazoles; Lactones; Pyrazoles; Structure-Activity Relationship; Sulfonamides; Sulfones; Thromboxane A2	2006
Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences? Naunyn-Schmiedeberg's archives of pharmacology, 2006, Volume: 373, Issue:1 Topics: Cardiovascular Diseases; Celecoxib; Cell Proliferation; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Heart Failure; Hemostasis; Humans; Hypertension; Lactones; Naproxen; Natriuretic Peptide, Brain; Peptide Fragments; Pyrazoles; Sulfonamides; Sulfones	2006
COX-2 inhibitors and the heart: are all coxibs the same? Postgraduate medical journal, 2006, Volume: 82, Issue:966 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Evidence-Based Medicine; Humans; Lactones; Pyrazoles; Sulfonamides; Sulfones	2006
Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA, 2006, Oct-04, Volume: 296, Issue:13 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Humans; Lactones; Naproxen; Pyrazoles; Risk; Sulfonamides; Sulfones	2006
COX-2 inhibitors and cardiovascular risk. Inferences based on biology and clinical studies. Thrombosis and haemostasis, 2006, Volume: 96, Issue:4 Topics: Animals; Blood Platelets; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug Labeling; Endothelium, Vascular; Epoprostenol; Humans; Lactones; Platelet Aggregation; Product Surveillance, Postmarketing; Pyrazoles; Randomized Controlled Trials as Topic; Risk Assessment; Sulfonamides; Sulfones; Thromboxane A2	2006
[What do we know about the cardiovascular toxicity of the NSAIDs?]. Presse medicale (Paris, France : 1983), 2006, Volume: 35, Issue:9 Spec No Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Case-Control Studies; Celecoxib; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Follow-Up Studies; Humans; Isoxazoles; Lactones; Meta-Analysis as Topic; Middle Aged; Naproxen; Pyrazoles; Randomized Controlled Trials as Topic; Risk Factors; Sulfonamides; Sulfones; Thrombosis; Time Factors	2006
[Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?]. Presse medicale (Paris, France : 1983), 2006, Volume: 35, Issue:9 Spec No Topics: Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Case-Control Studies; Celecoxib; Cohort Studies; Cyclooxygenase 2 Inhibitors; Diclofenac; Edema; Heart Failure; Humans; Hypertension; Isoxazoles; Lactones; Meta-Analysis as Topic; Middle Aged; Odds Ratio; Placebos; Prospective Studies; Pyrazoles; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Risk Factors; Sulfonamides; Sulfones; Thrombosis; Time Factors	2006
Coxibs and heart disease: what we have learned and what else we need to know. Journal of the American College of Cardiology, 2007, Jan-02, Volume: 49, Issue:1 Topics: Animals; Cardiovascular Diseases; Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Humans; Lactones; Risk Assessment; Sulfones	2007
What have we learnt from Vioxx? BMJ (Clinical research ed.), 2007, Jan-20, Volume: 334, Issue:7585 Topics: Cardiovascular Diseases; Compensation and Redress; Cyclooxygenase 2 Inhibitors; Drug Industry; Humans; Interprofessional Relations; Lactones; Risk Factors; Scientific Misconduct; Sulfones; Time Factors; United Kingdom; United States	2007
COX-2 inhibitors and cardiovascular risk. Sub-cellular biochemistry, 2007, Volume: 42 Topics: Blood Pressure; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Humans; Isoxazoles; Lactones; Lysine; Risk Factors; Sulfonamides; Sulfones; Water-Electrolyte Balance	2007
Mechanisms underlying the cardiovascular effects of COX-inhibition: benefits and risks. Current pharmaceutical design, 2007, Volume: 13, Issue:22 Topics: Atherosclerosis; Cardiovascular Diseases; Consumer Product Safety; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Approval; Endothelium, Vascular; Humans; Lactones; Prostaglandins; Risk Assessment; Signal Transduction; Sulfones; Thrombosis; Vasodilation	2007
[Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?]. Presse medicale (Paris, France : 1983), 2006, Volume: 35 Suppl 1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cerebrovascular Disorders; Coronary Disease; Cyclooxygenase 2 Inhibitors; Drug Tolerance; Humans; Kidney Diseases; Lactones; Risk Factors; Sulfones	2006
Cardiovascular disease in patients with spondyloarthropathies. Joint bone spine, 2008, Volume: 75, Issue:1 Topics: Antirheumatic Agents; Atherosclerosis; Atrioventricular Block; Cardiovascular Diseases; Comorbidity; Cyclooxygenase 2 Inhibitors; Genetic Predisposition to Disease; Heart Conduction System; Heart Valve Diseases; HLA-B27 Antigen; Humans; Lactones; Risk Factors; Smoking; Spondylarthropathies; Sulfones; Tumor Necrosis Factor-alpha	2008
Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. The Journal of clinical investigation, 2001, Volume: 108, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Blood Platelets; Cardiovascular Diseases; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Depression, Chemical; Dinoprostone; Epoprostenol; Gastric Mucosa; Gastrointestinal Hemorrhage; Humans; Incidence; Intestinal Mucosa; Isoenzymes; Lactones; Membrane Proteins; Peptic Ulcer; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Pyrazoles; Randomized Controlled Trials as Topic; Substrate Specificity; Sulfonamides; Sulfones; Thromboembolism; Thromboxane A2; Treatment Outcome	2001
The coxibs, selective inhibitors of cyclooxygenase-2. The New England journal of medicine, 2001, Aug-09, Volume: 345, Issue:6 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Interactions; Female; Gastrointestinal Diseases; Humans; Isoenzymes; Kidney; Lactones; Male; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones; Treatment Outcome	2001
Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation, 2001, Nov-06, Volume: 104, Issue:19 Topics: Aged; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Chronic Disease; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Clinical Trials, Phase IV as Topic; Comorbidity; Cyclooxygenase 1; Cyclooxygenase 2; Female; Humans; Isoenzymes; Lactones; Low Back Pain; Male; Membrane Proteins; Middle Aged; Naproxen; Osteoarthritis; Proportional Hazards Models; Prostaglandin-Endoperoxide Synthases; Randomized Controlled Trials as Topic; Risk; Sulfones; Thrombosis	2001
Translational medicine: targetting cyclo-oxygenase isozymes to prevent cancer. QJM : monthly journal of the Association of Physicians, 2002, Volume: 95, Issue:5 Topics: Arachidonic Acid; Aspirin; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Design; Humans; Isoenzymes; Lactones; Membrane Proteins; Neoplasms; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Pyrazoles; Randomized Controlled Trials as Topic; Sulfonamides; Sulfones	2002
Considerations for the safe prescribing and use of COX-2-specific inhibitors. The Medical journal of Australia, 2002, Apr-01, Volume: 176, Issue:7 Topics: Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Gastrointestinal Diseases; Humans; Isoenzymes; Kidney Diseases; Lactones; Membrane Proteins; Practice Patterns, Physicians'; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones	2002

Trials

5 trial(s) available for rofecoxib and Cardiovascular Diseases

Article	Year
Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. Lancet (London, England), 2008, Nov-15, Volume: 372, Issue:9651 Topics: Cardiovascular Diseases; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Data Interpretation, Statistical; Double-Blind Method; Female; Follow-Up Studies; Humans; Lactones; Male; Middle Aged; Sulfones	2008
Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial. Annals of internal medicine, 2003, Oct-07, Volume: 139, Issue:7 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Gastrointestinal Diseases; Humans; Hypertension; Lactones; Male; Middle Aged; Naproxen; Osteoarthritis; Prospective Studies; Sulfones	2003
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. The New England journal of medicine, 2005, Mar-17, Volume: 352, Issue:11 Topics: Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Cyclooxygenase Inhibitors; Double-Blind Method; Female; Humans; Incidence; Lactones; Male; Middle Aged; Proportional Hazards Models; Risk; Secondary Prevention; Single-Blind Method; Sulfones; Thrombosis	2005
Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer. The New England journal of medicine, 2007, Jul-26, Volume: 357, Issue:4 Topics: Adenoma; Aged; Cardiovascular Diseases; Chemotherapy, Adjuvant; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Female; Follow-Up Studies; Humans; Incidence; Lactones; Male; Middle Aged; Neoplasm Recurrence, Local; Risk; Sulfones	2007
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. The New England journal of medicine, 2000, 11-23, Volume: 343, Issue:21 Topics: Adult; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Duodenal Obstruction; Female; Gastric Outlet Obstruction; Gastrointestinal Diseases; Gastrointestinal Hemorrhage; Humans; Isoenzymes; Lactones; Male; Membrane Proteins; Middle Aged; Naproxen; Peptic Ulcer; Proportional Hazards Models; Prostaglandin-Endoperoxide Synthases; Sulfones	2000

Other Studies

105 other study(ies) available for rofecoxib and Cardiovascular Diseases

Article	Year
Fool Me Twice? The Reemergence of Rofecoxib and the Orphan Drug Act. Annals of internal medicine, 2019, 10-15, Volume: 171, Issue:8 Topics: Arthritis; Cardiovascular Diseases; Chronic Pain; Hemophilia A; Humans; Lactones; Orphan Drug Production; Sulfones; United States	2019
Disruption of elastic lamellae in aorta and dysfunction of vaso-regulation by rofecoxib in rats. The Journal of toxicological sciences, 2013, Volume: 38, Issue:5 Topics: Administration, Oral; Age Factors; Amino Acids; Animals; Aorta; Arterial Pressure; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Desmosine; Elastic Tissue; Elasticity; Elastin; Humans; Injections, Subcutaneous; Isodesmosine; Lactones; Male; Rats; Rats, Sprague-Dawley; Sulfones	2013
The Vioxx® legacy: Enduring lessons from the not so distant past. Cardiology journal, 2014, Volume: 21, Issue:2 Topics: Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Drug Approval; History, 21st Century; Humans; Lactones; Patient Safety; Risk Assessment; Safety-Based Drug Withdrawals; Sulfones	2014
Causal Inference for Meta-Analysis and Multi-Level Data Structures, with Application to Randomized Studies of Vioxx. Psychometrika, 2017, Volume: 82, Issue:2 Topics: Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Humans; Lactones; Male; Meta-Analysis as Topic; Psychometrics; Randomized Controlled Trials as Topic; Risk Factors; Sulfones	2017
Influence of regulatory measures on the rate of spontaneous adverse drug reaction reporting in Italy. Drug safety, 2008, Volume: 31, Issue:7 Topics: Adverse Drug Reaction Reporting Systems; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Cough; Cyclooxygenase 2 Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Italy; Lactones; Liver; Rhabdomyolysis; Sulfonamides; Sulfones	2008
Changes in the characteristics of patients prescribed selective cyclooxygenase 2 inhibitors after the 2004 withdrawal of rofecoxib. Arthritis and rheumatism, 2008, Aug-15, Volume: 59, Issue:8 Topics: Adolescent; Adult; Aged; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Databases, Factual; Drug Prescriptions; Drug Utilization Review; Female; Gastrointestinal Diseases; Humans; Incidence; Lactones; Logistic Models; Male; Middle Aged; Rheumatic Diseases; Risk Factors; Sulfones; United Kingdom	2008
Postmarketing surveillance of serious adverse events associated with the use of rofecoxib from 1999-2002. Current medical research and opinion, 2009, Volume: 25, Issue:6 Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Drug Interactions; Drug Recalls; Drug-Related Side Effects and Adverse Reactions; Female; Hemorrhage; Humans; Lactones; Male; Middle Aged; Product Surveillance, Postmarketing; Risk Factors; Severity of Illness Index; Stroke; Sulfones; Time Factors	2009
Differential effects of p38 mitogen-activated protein kinase and cyclooxygenase 2 inhibitors in a model of cardiovascular disease. The Journal of pharmacology and experimental therapeutics, 2009, Volume: 330, Issue:3 Topics: Aldosterone; Animals; Blood Pressure; Cardiovascular Diseases; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclopropanes; Cytokines; Electrocardiography; Endothelium, Vascular; Enzyme Inhibitors; Interleukin-1beta; Kidney Function Tests; Lactones; Lipid Metabolism; Male; p38 Mitogen-Activated Protein Kinases; Pyridines; Rats; Rats, Inbred SHR; Renin; Sulfones; Vasodilation; Ventricular Remodeling	2009
Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. Circulation. Cardiovascular quality and outcomes, 2009, Volume: 2, Issue:3 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cohort Studies; Coronary Artery Disease; Cyclooxygenase 2 Inhibitors; Diclofenac; Female; Follow-Up Studies; Hospitalization; Humans; Ibuprofen; Incidence; Lactones; Male; Middle Aged; Myocardial Infarction; Naproxen; Outpatients; Pyrazoles; Retrospective Studies; Risk Factors; Stroke; Sulfonamides; Sulfones; Tennessee	2009
Changes in physicians' practice of prescribing cyclooxygenase-2 inhibitor after market withdrawal of rofecoxib: a retrospective study of physician-patient pairs in Taiwan. Clinical therapeutics, 2009, Volume: 31, Issue:11 Topics: Aged; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Databases, Factual; Drug Utilization; Female; Humans; Insurance Claim Review; Lactones; Male; Middle Aged; National Health Programs; Patients; Physicians; Practice Patterns, Physicians'; Prescriptions; Product Recalls and Withdrawals; Pyrazoles; Regression Analysis; Retrospective Studies; Sulfonamides; Sulfones; Taiwan	2009
Metabolic profiling of murine plasma reveals an unexpected biomarker in rofecoxib-mediated cardiovascular events. Proceedings of the National Academy of Sciences of the United States of America, 2010, Sep-28, Volume: 107, Issue:39 Topics: Animals; Biomarkers; Bleeding Time; Blood Coagulation; Blood Platelets; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Hydroxyeicosatetraenoic Acids; Lactones; Male; Mice; Mice, Inbred C57BL; Platelet Aggregation; Sulfones	2010
Persistence of cardiovascular risk after rofecoxib discontinuation. Archives of internal medicine, 2010, Dec-13, Volume: 170, Issue:22 Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Drug Administration Schedule; Female; Humans; Incidence; Kaplan-Meier Estimate; Lactones; Male; Middle Aged; Odds Ratio; Proportional Hazards Models; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Sulfones; Time Factors	2010
Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib. European heart journal, 2012, Volume: 33, Issue:15 Topics: Atrial Fibrillation; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Epidemiologic Methods; Female; Heart Failure; Humans; Lactones; Male; Middle Aged; Myocardial Infarction; Prognosis; Pyrazoles; Safety-Based Drug Withdrawals; Stroke; Sulfonamides; Sulfones; Sweden	2012
Under-reporting of cardiovascular events in the rofecoxib Alzheimer disease studies. American heart journal, 2012, Volume: 164, Issue:2 Topics: Adverse Drug Reaction Reporting Systems; Alzheimer Disease; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Humans; Intention to Treat Analysis; Lactones; Randomized Controlled Trials as Topic; Risk Factors; Sulfones; Thrombosis	2012
Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation, 2002, Jul-30, Volume: 106, Issue:5 Topics: Aspirin; Cardiovascular Diseases; Controlled Clinical Trials as Topic; Cyclooxygenase Inhibitors; Humans; Lactones; Reproducibility of Results; Research Design; Sulfones; Thrombosis	2002
Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice. The American journal of managed care, 2002, Volume: 8, Issue:15 Suppl Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cross-Sectional Studies; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Data Collection; Drug Interactions; Female; Humans; Hypertension; Isoenzymes; Lactones; Male; Membrane Proteins; Middle Aged; Osteoarthritis; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Risk Assessment; Risk Factors; Sulfonamides; Sulfones; United States	2002
Cyclooxygenase-2 inhibition attenuates lipopolysaccharide-induced cardiovascular failure. Hypertension (Dallas, Tex. : 1979), 2002, Volume: 40, Issue:6 Topics: Animals; Blood Pressure; Cardiovascular Diseases; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Gene Expression; Heart Rate; Inflammation Mediators; Injections, Intravenous; Isoenzymes; Lactones; Lipopolysaccharides; Male; Membrane Proteins; Nitrates; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitrites; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sulfones; Transaminases	2002
The prevalence of cardiorenal risk factors in patients prescribed nonsteroidal anti-inflammatory drugs: data from managed care. Clinical therapeutics, 2003, Volume: 25, Issue:1 Topics: Adult; Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Female; Humans; Hypertension; Isoenzymes; Kidney Diseases; Lactones; Male; Managed Care Programs; Membrane Proteins; Middle Aged; Osteoarthritis; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Retrospective Studies; Risk Factors; Sulfonamides; Sulfones; United States	2003
[Selective Cox-2 inhibitor in osteoarthritis and rheumatoid arthritis. No increased risk for the heart]. MMW Fortschritte der Medizin, 2003, Mar-13, Volume: 145, Issue:11 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celecoxib; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Humans; Lactones; Middle Aged; Osteoarthritis; Pyrazoles; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Sulfonamides; Sulfones	2003
Summaries for patients. Gastrointestinal side effects of rofecoxib and naproxen. Annals of internal medicine, 2003, Oct-07, Volume: 139, Issue:7 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Gastrointestinal Diseases; Humans; Hypertension; Lactones; Male; Middle Aged; Naproxen; Osteoarthritis; Prospective Studies; Sulfones	2003
Matters of the heart: assessing the cardiovascular safety of new drugs. American heart journal, 2003, Volume: 146, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Gastrointestinal Diseases; Humans; Lactones; Sulfones; Thrombosis	2003
Applying a research ethics committee approach to a medical practice controversy: the case of the selective COX-2 inhibitor rofecoxib. Journal of medical ethics, 2004, Volume: 30, Issue:2 Topics: Cardiovascular Diseases; Cyclooxygenase Inhibitors; Drug Industry; Ethics Committees, Research; Humans; Informed Consent; Lactones; Marketing; Professional Practice; Publishing; Sulfones	2004
Coxibs and cardiovascular disease. The New England journal of medicine, 2004, Oct-21, Volume: 351, Issue:17 Topics: Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Approval; Drug Industry; Epoprostenol; Gastrointestinal Diseases; Humans; Isoenzymes; Isoxazoles; Lactones; Membrane Proteins; Naproxen; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Risk; Sulfonamides; Sulfones; Thromboxane A2; United States; United States Food and Drug Administration	2004
Unnecessary withdrawal of Vioxx. The New Zealand medical journal, 2004, Oct-22, Volume: 117, Issue:1204 Topics: Cardiovascular Diseases; Data Interpretation, Statistical; Drug Approval; Humans; Lactones; Sulfones	2004
Cardiovascular safety of rofecoxib (Vioxx): lessons learned and unanswered questions: we need processes in place to follow up suspicions about serious adverse events. The Medical journal of Australia, 2004, Nov-15, Volume: 181, Issue:10 Topics: Cardiovascular Diseases; Cyclooxygenase Inhibitors; Humans; Lactones; Product Surveillance, Postmarketing; Risk Assessment; Sulfones	2004
COX-2-derived prostacyclin confers atheroprotection on female mice. Science (New York, N.Y.), 2004, Dec-10, Volume: 306, Issue:5703 Topics: Animals; Antioxidants; Arteriosclerosis; Cardiovascular Diseases; Cells, Cultured; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Epoprostenol; Estradiol; Estrogen Receptor alpha; Female; Hydrogen Peroxide; Isoenzymes; Lactones; Lipid Peroxidation; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Ovariectomy; Oxidative Stress; Platelet Activation; Prostaglandin-Endoperoxide Synthases; Receptors, Epoprostenol; Receptors, LDL; Sex Characteristics; Sulfones	2004
Lawsuits mount in wake of rofecoxib (Vioxx) withdrawal. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2004, Nov-23, Volume: 171, Issue:11 Topics: Canada; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Drug Industry; Humans; Lactones; Liability, Legal; Product Surveillance, Postmarketing; Sulfones	2004
Vioxx risk could signify trouble in class. Nature reviews. Drug discovery, 2004, Volume: 3, Issue:11 Topics: Cardiovascular Diseases; Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Industry; Humans; Isoenzymes; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Risk; Sulfones	2004
[Withdrawal of rofecoxib: a sign to be careful with coxibs in patients with increased cardiovascular risk]. Nederlands tijdschrift voor geneeskunde, 2004, Oct-30, Volume: 148, Issue:44 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Humans; Lactones; Risk Assessment; Risk Factors; Sulfones	2004
[Slime fight in the lay media. Were the Vioxx fatal cases kept secret?]. MMW Fortschritte der Medizin, 2004, Oct-21, Volume: 146, Issue:43 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Controlled Clinical Trials as Topic; Cyclooxygenase Inhibitors; Humans; Lactones; Longitudinal Studies; Placebos; Retrospective Studies; Risk Factors; Sulfones; Time Factors	2004
Public interest group accuses FDA of trying to discredit whistleblower. BMJ (Clinical research ed.), 2004, Nov-27, Volume: 329, Issue:7477 Topics: California; Cardiovascular Diseases; Consumer Organizations; Lactones; Sulfones; United States; United States Food and Drug Administration; Whistleblowing	2004
A world without Vioxx: to COX-2 or not to COX-2? Cleveland Clinic journal of medicine, 2004, Volume: 71, Issue:11 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Gastrointestinal Diseases; Humans; Lactones; Osteoarthritis; Sulfones	2004
[The case of Vioxx requires consideration]. Lakartidningen, 2004, Nov-04, Volume: 101, Issue:45 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Drug and Narcotic Control; Drug Industry; Drug Information Services; Humans; Lactones; Marketing; Risk Factors; Sulfones	2004
COX-2 selective inhibitors cardiac toxicity: getting to the heart of the matter. Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques, 2004, Oct-29, Volume: 7, Issue:3 Topics: Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Incidence; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Sulfones	2004
Clinical trials. Nail-biting time for trials of COX-2 drugs. Science (New York, N.Y.), 2004, Dec-03, Volume: 306, Issue:5702 Topics: Alzheimer Disease; Anticarcinogenic Agents; Cardiovascular Diseases; Celecoxib; Controlled Clinical Trials as Topic; Cyclooxygenase Inhibitors; Humans; Intestinal Polyps; Lactones; Neoplasms; Patient Selection; Pyrazoles; Sulfonamides; Sulfones	2004
Lessons from the withdrawal of rofecoxib: Observational studies should not be forgotten. BMJ (Clinical research ed.), 2004, Dec-04, Volume: 329, Issue:7478 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Drug Approval; Humans; Lactones; Randomized Controlled Trials as Topic; Sulfones	2004
[MSD about Vioxx--important to learn from the experience without hindsight]. Lakartidningen, 2004, Nov-11, Volume: 101, Issue:46 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Drug and Narcotic Control; Drug Information Services; Humans; Lactones; Safety; Sulfones; Sweden	2004
Rofecoxib, Merck, and the FDA. The New England journal of medicine, 2004, Dec-30, Volume: 351, Issue:27 Topics: Cardiovascular Diseases; Cyclooxygenase Inhibitors; Drug Approval; Drug Industry; History, 20th Century; History, 21st Century; Humans; Lactones; Randomized Controlled Trials as Topic; Sulfones; United States; United States Food and Drug Administration	2004
Rofecoxib, Merck, and the FDA. The New England journal of medicine, 2004, Dec-30, Volume: 351, Issue:27 Topics: Cardiovascular Diseases; Cyclooxygenase Inhibitors; Drug Approval; Drug Industry; Drug Labeling; History, 21st Century; Humans; Intestinal Perforation; Lactones; Product Surveillance, Postmarketing; Sulfones; United States; United States Food and Drug Administration	2004
Rofecoxib, Merck, and the FDA. The New England journal of medicine, 2004, Dec-30, Volume: 351, Issue:27 Topics: Aspirin; Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Drug Approval; Drug Interactions; Gastrointestinal Diseases; History, 20th Century; History, 21st Century; Humans; Lactones; Platelet Aggregation Inhibitors; Pyrazoles; Sulfonamides; Sulfones; United States; United States Food and Drug Administration	2004
[Reflections on COX, Vioxx and Relifex. Increased cardiovascular risk following selective COX-2 inhibition]. Lakartidningen, 2004, Nov-25, Volume: 101, Issue:48 Topics: Anti-Inflammatory Agents, Non-Steroidal; Butanones; Cardiovascular Diseases; Gastrointestinal Diseases; Humans; Lactones; Nabumetone; Risk Factors; Sulfones	2004
[Rofecoxib--a recall with implications]. Ugeskrift for laeger, 2004, Dec-06, Volume: 166, Issue:50 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Drug and Narcotic Control; Humans; Lactones; Risk Factors; Sulfones	2004
Under surveillance. Nature biotechnology, 2005, Volume: 23, Issue:1 Topics: Biotechnology; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Drug Approval; Drug Industry; Humans; Lactones; Product Surveillance, Postmarketing; Sulfones; United States; United States Food and Drug Administration	2005
Sentinel systems are needed for long term adverse drug reactions. BMJ (Clinical research ed.), 2005, Jan-29, Volume: 330, Issue:7485 Topics: Adverse Drug Reaction Reporting Systems; Cardiovascular Diseases; Cost-Benefit Analysis; Drug Approval; Humans; Lactones; Sulfones	2005
[Vision impairment by COX-2 inhibitor and the sequelae of voluntary Vioxx recall]. Klinische Monatsblatter fur Augenheilkunde, 2005, Volume: 222, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Colonic Polyps; Costs and Cost Analysis; Cyclooxygenase Inhibitors; Drug and Narcotic Control; Drug Industry; Germany; Humans; Lactones; Long-Term Care; Multicenter Studies as Topic; Pyrazoles; Randomized Controlled Trials as Topic; Retinal Vein Occlusion; Risk; Secondary Prevention; Sulfonamides; Sulfones; United States; Vision Disorders	2005
VIOXX and cardiovascular events: a class effect? Joint bone spine, 2005, Volume: 72, Issue:1 Topics: Cardiovascular Diseases; Cyclooxygenase Inhibitors; Humans; Lactones; Randomized Controlled Trials as Topic; Sulfones	2005
Coxibs and caution. Journal of the Royal Society of Medicine, 2005, Volume: 98, Issue:2 Topics: Cardiovascular Diseases; Cyclooxygenase Inhibitors; Drug Approval; Humans; Lactones; Sulfones	2005
Don't throw out the baby with the bathwater! Journal of pediatric hematology/oncology, 2005, Volume: 27, Issue:2 Topics: Advertising; Cardiovascular Diseases; Child; Child Welfare; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Decision Making; Drug Approval; Drug Industry; Humans; Lactones; Neoplasms; Risk Factors; Sulfones	2005
COX-2 inhibitors: cancer prevention or cardiovascular risk? The Lancet. Oncology, 2005, Volume: 6, Issue:2 Topics: Adenoma; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Lactones; Membrane Proteins; Neoplasms; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Randomized Controlled Trials as Topic; Sulfonamides; Sulfones	2005
[Vioxx: reasons for a premature retirement]. Medecine sciences : M/S, 2005, Volume: 21, Issue:1 Topics: Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Humans; Lactones; Sulfones	2005
COX-2 inhibitors--lessons in drug safety. The New England journal of medicine, 2005, Mar-17, Volume: 352, Issue:11 Topics: Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Approval; Gastrointestinal Hemorrhage; Humans; Isoxazoles; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Publishing; Pyrazoles; Randomized Controlled Trials as Topic; Research Design; Sulfonamides; Sulfones; United States; United States Food and Drug Administration	2005
COX-2 inhibitors--a lesson in unexpected problems. The New England journal of medicine, 2005, Mar-17, Volume: 352, Issue:11 Topics: Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Approval; Gastrointestinal Hemorrhage; Humans; Isoxazoles; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones	2005
The withdrawal of rofecoxib. Pharmacoepidemiology and drug safety, 2005, Volume: 14, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Cyclooxygenase 2 Inhibitors; Death, Sudden, Cardiac; Drug Industry; Humans; Lactones; Naproxen; Pharmacoepidemiology; Product Surveillance, Postmarketing; Sulfones	2005
Drug safety. FDA panel urges caution on many anti-inflammatory drugs. Science (New York, N.Y.), 2005, Feb-25, Volume: 307, Issue:5713 Topics: Advisory Committees; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Drug and Narcotic Control; Drug Labeling; Humans; Isoxazoles; Lactones; Pyrazoles; Stroke; Sulfonamides; Sulfones; United States; United States Food and Drug Administration	2005
The lessons of Vioxx. Cutis, 2005, Volume: 75, Issue:1 Topics: Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Consumer Product Safety; Humans; Lactones; Product Surveillance, Postmarketing; Randomized Controlled Trials as Topic; Stroke; Sulfones	2005
Factors associated with celecoxib and rofecoxib utilization. The Annals of pharmacotherapy, 2005, Volume: 39, Issue:4 Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Case-Control Studies; Celecoxib; Confidence Intervals; Databases, Factual; Drug Prescriptions; Female; Health Care Sector; Humans; Lactones; Logistic Models; Male; Middle Aged; Odds Ratio; Pyrazoles; Risk Factors; Sulfonamides; Sulfones	2005
Cyclooxygenase-2 inhibitors and cardiovascular risk. The Canadian journal of cardiology, 2005, Volume: 21, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Australia; Canada; Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Drug Industry; Drug Labeling; Humans; Incidence; Lactones; Product Surveillance, Postmarketing; Pyrazoles; Risk Factors; Sulfonamides; Sulfones	2005
COX-2 inhibitors--first, do no harm. The New Zealand medical journal, 2005, Mar-11, Volume: 118, Issue:1211 Topics: Cardiovascular Diseases; Cyclooxygenase Inhibitors; Drug and Narcotic Control; Humans; Lactones; New Zealand; Risk; Sulfones	2005
[VIOXX written off--and what next? COX-2 inhibitors and cardiovascular diseases]. Casopis lekaru ceskych, 2005, Volume: 144, Issue:1 Topics: Cardiovascular Diseases; Cyclooxygenase Inhibitors; Humans; Lactones; Sulfones	2005
COX-2 inhibitors and cardiovascular toxicity: a class effect? South Dakota journal of medicine, 2005, Volume: 58, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Humans; Lactones; Pyrazoles; Sulfonamides; Sulfones	2005
Raising the safety bar--the FDA's coxib meeting. The New England journal of medicine, 2005, Mar-31, Volume: 352, Issue:13 Topics: Advertising; Advisory Committees; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Drug Approval; Drug Industry; Drug Labeling; Humans; Isoxazoles; Lactones; Product Surveillance, Postmarketing; Pyrazoles; Sulfonamides; Sulfones; United States; United States Food and Drug Administration	2005
Learning the value of drugs--is rofecoxib a regulatory success story? The New England journal of medicine, 2005, Mar-31, Volume: 352, Issue:13 Topics: Cardiovascular Diseases; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Drug Approval; Drug Industry; Government Regulation; Humans; Lactones; Product Surveillance, Postmarketing; Sulfones; United States; United States Food and Drug Administration	2005
Institutional review boards must conduct safety review. Human research report, 2005, Volume: 20, Issue:2 Topics: Cardiovascular Diseases; Celecoxib; Clinical Trials as Topic; Clinical Trials Data Monitoring Committees; Cyclooxygenase Inhibitors; Ethics Committees, Research; Humans; Lactones; National Institutes of Health (U.S.); Pyrazoles; Research Subjects; Safety; Sulfonamides; Sulfones; United States; United States Food and Drug Administration	2005
Incidence of thrombotic cardiovascular events in patients taking celecoxib compared with those taking rofecoxib: interim results from the New Zealand Intensive Medicines Monitoring Programme. Drug safety, 2005, Volume: 28, Issue:5 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cohort Studies; Female; Humans; Intracranial Thrombosis; Lactones; Male; Middle Aged; New Zealand; Product Surveillance, Postmarketing; Pyrazoles; Sulfonamides; Sulfones; Surveys and Questionnaires	2005
[Cardiovascular risks of Cox-2-antagonists. Opinion on the marketed name rofecoxib, and its market-withdrawn valdecoxib and the actual therapeutic restrictions]. Zeitschrift fur Rheumatologie, 2005, Volume: 64, Issue:4 Topics: Antirheumatic Agents; Cardiovascular Diseases; Consumer Product Safety; Cyclooxygenase Inhibitors; Drug Approval; Germany; Humans; Isoxazoles; Lactones; Practice Guidelines as Topic; Practice Patterns, Physicians'; Rheumatic Diseases; Sulfonamides; Sulfones	2005
The trade-off between cardiovascular and gastrointestinal effects of rofecoxib. Pharmacoepidemiology and drug safety, 2005, Volume: 14, Issue:7 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Comorbidity; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Family Practice; Female; Gastrointestinal Diseases; Humans; Lactones; Male; Membrane Proteins; Middle Aged; Prostaglandin-Endoperoxide Synthases; Retrospective Studies; Risk Assessment; Sulfones	2005
Report of specific cardiovascular outcomes of the ADVANTAGE trial. Annals of internal medicine, 2005, Jul-19, Volume: 143, Issue:2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Gastrointestinal Diseases; Humans; Lactones; Naproxen; Osteoarthritis; Sulfones	2005
Cardiovascular risk associated with celecoxib. The New England journal of medicine, 2005, Jun-23, Volume: 352, Issue:25 Topics: Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Data Interpretation, Statistical; Humans; Lactones; Pyrazoles; Risk; Sulfonamides; Sulfones	2005
Painkiller verdict shows mistrust of Merck. Nature, 2005, Aug-25, Volume: 436, Issue:7054 Topics: Arrhythmias, Cardiac; Cardiovascular Diseases; Disclosure; Drug Industry; Humans; Lactones; Male; Sulfones; Trust	2005
The Vioxx debacle revisited. The American journal of medicine, 2005, Volume: 118, Issue:9 Topics: Cardiovascular Diseases; Cyclooxygenase Inhibitors; Drug Approval; Humans; Lactones; Physician's Role; Social Responsibility; Sulfones; United States; United States Food and Drug Administration	2005
The Vioxx debacle revisited. The American journal of medicine, 2005, Volume: 118, Issue:9 Topics: Cardiovascular Diseases; Cyclooxygenase Inhibitors; Humans; Lactones; Product Surveillance, Postmarketing; Social Responsibility; Sulfones; United States	2005
The lessons of Vioxx. The New England journal of medicine, 2005, Sep-29, Volume: 353, Issue:13 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Drug Industry; Gastrointestinal Diseases; Humans; Lactones; Marketing; Naproxen; Product Surveillance, Postmarketing; Sulfones; United States; United States Food and Drug Administration	2005
Journal grows suspicious of Vioxx data. Nature, 2005, Dec-15, Volume: 438, Issue:7070 Topics: Cardiovascular Diseases; Clinical Trials as Topic; Drug Industry; Humans; Lactones; Periodicals as Topic; Sulfones; Time Factors; United States; United States Food and Drug Administration	2005
Scientific publishing. Echoing other cases, NEJM says Vioxx Safety data withheld. Science (New York, N.Y.), 2005, Dec-16, Volume: 310, Issue:5755 Topics: Authorship; Cardiovascular Diseases; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Databases, Factual; Drug Industry; Editorial Policies; Humans; Internet; Lactones; National Institutes of Health (U.S.); Periodicals as Topic; Publishing; Registries; Sulfones; Surveys and Questionnaires; United States	2005
[Role of cyclo-oxygenases in the effects of angiotensin II]. Medecine sciences : M/S, 2006, Volume: 22, Issue:1 Topics: Angiotensin II; Animals; Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Humans; Lactones; Models, Biological; Oxidative Stress; Sulfones	2006
Expression of concern reaffirmed. The New England journal of medicine, 2006, Mar-16, Volume: 354, Issue:11 Topics: Arthritis, Rheumatoid; Cardiovascular Diseases; Gastrointestinal Diseases; Humans; Lactones; Myocardial Infarction; Naproxen; Research Design; Sulfones; Thromboembolism	2006
Response to expression of concern regarding VIGOR study. The New England journal of medicine, 2006, Mar-16, Volume: 354, Issue:11 Topics: Arthritis, Rheumatoid; Cardiovascular Diseases; Data Interpretation, Statistical; Gastrointestinal Diseases; Humans; Lactones; Myocardial Infarction; Naproxen; Sulfones	2006
Cardiovascular events associated with long-term use of celecoxib, rofecoxib and meloxicam in Taiwan: an observational study. Drug safety, 2006, Volume: 29, Issue:3 Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Angina Pectoris; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Databases, Factual; Female; Humans; Insurance, Pharmaceutical Services; Ischemic Attack, Transient; Lactones; Male; Meloxicam; Middle Aged; Myocardial Infarction; National Health Programs; Proportional Hazards Models; Pyrazoles; Risk Assessment; Stroke; Sulfonamides; Sulfones; Taiwan; Thiazines; Thiazoles; Time Factors	2006
Lessons to learn from the COX-2 saga. Yes, FDA reforms are needed. And marketing distorts how medications are used. But one moral to the story is that all drugs have risks. Harvard health letter, 2005, Volume: 30, Issue:5 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug-Related Side Effects and Adverse Reactions; Humans; Isoxazoles; Lactones; Marketing of Health Services; Naproxen; Pyrazoles; Risk Assessment; Sulfonamides; Sulfones; United States; United States Food and Drug Administration	2005
Celecoxib shown effective in preventing colon polyps. Journal of the National Cancer Institute, 2006, May-17, Volume: 98, Issue:10 Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Cardiovascular Diseases; Celecoxib; Colonic Polyps; Cyclooxygenase Inhibitors; Humans; Lactones; Multicenter Studies as Topic; Myocardial Infarction; National Institutes of Health (U.S.); Pyrazoles; Randomized Controlled Trials as Topic; Research Support as Topic; Stroke; Sulfonamides; Sulfones; United States	2006
[Use of rofecoxib in family practice in the north of Netherlands, 2000-2004: background and consequences]. Nederlands tijdschrift voor geneeskunde, 2006, May-06, Volume: 150, Issue:18 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Databases, Factual; Dose-Response Relationship, Drug; Drug Prescriptions; Family Practice; Female; Humans; Lactones; Logistic Models; Longitudinal Studies; Male; Netherlands; Risk Factors; Sulfones; Time Factors	2006
The patient's perspective on the recall of Vioxx. The Journal of rheumatology, 2006, Volume: 33, Issue:6 Topics: Aged; Cardiovascular Diseases; Communication; Cyclooxygenase 2 Inhibitors; Drug and Narcotic Control; Female; Humans; Lactones; Male; Middle Aged; Osteoarthritis, Hip; Osteoarthritis, Knee; Patient Education as Topic; Patients; Public Opinion; Sulfones	2006
Adverse cardiovascular effects of rofecoxib. The New England journal of medicine, 2006, Jul-13, Volume: 355, Issue:2 Topics: Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Data Interpretation, Statistical; Humans; Lactones; Randomized Controlled Trials as Topic; Sulfones	2006
Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk. Drug safety, 2006, Volume: 29, Issue:7 Topics: Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cohort Studies; Cyclooxygenase 2 Inhibitors; Etodolac; Female; Humans; Ibuprofen; Lactones; Male; Middle Aged; Naproxen; Pyrazoles; Sulfonamides; Sulfones; Time Factors; United States; Veterans	2006
Adverse cardiovascular effects of rofecoxib. The New England journal of medicine, 2006, Jul-13, Volume: 355, Issue:2 Topics: Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Data Interpretation, Statistical; Humans; Lactones; Randomized Controlled Trials as Topic; Sulfones	2006
How the New England Journal missed warning signs on Vioxx: medical weekly waited years to report flaws in article that praised pain drug; Merck seen as "punching bag". Wall Street journal (Eastern ed.), 2006, May-15 Topics: Cardiovascular Diseases; Clinical Trials as Topic; Cyclooxygenase 2 Inhibitors; Drug Industry; Editorial Policies; Humans; Lactones; Peer Review, Research; Periodicals as Topic; Scientific Misconduct; Sulfones	2006
The effect of the withdrawal of rofecoxib on prescribing patterns of COX-2 inhibitors in Scotland. British journal of clinical pharmacology, 2006, Volume: 62, Issue:3 Topics: Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Drug Approval; Humans; Lactones; Practice Patterns, Physicians'; Scotland; Sulfones	2006
[Assessment and truth -- how many cardio- and cerebrovascular events are in fact to be led back to taking rofecoxib]. Medizinische Klinik (Munich, Germany : 1983), 2006, Aug-15, Volume: 101, Issue:8 Topics: Cardiovascular Diseases; Cerebrovascular Disorders; Confidence Intervals; Controlled Clinical Trials as Topic; Cyclooxygenase 2 Inhibitors; Databases as Topic; Humans; Lactones; Myocardial Infarction; Retrospective Studies; Risk Assessment; Risk Factors; Sulfones; Time Factors	2006
[How many harmed by rofecoxib in Germany?]. Medizinische Klinik (Munich, Germany : 1983), 2006, Aug-15, Volume: 101, Issue:8 Topics: Cardiovascular Diseases; Case-Control Studies; Cohort Studies; Confidence Intervals; Controlled Clinical Trials as Topic; Cyclooxygenase 2 Inhibitors; Databases as Topic; Germany; Humans; Lactones; Middle Aged; Models, Theoretical; Myocardial Infarction; Prospective Studies; Risk; Sulfones	2006
[Overestimated]. Medizinische Klinik (Munich, Germany : 1983), 2006, Aug-15, Volume: 101, Issue:8 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Controlled Clinical Trials as Topic; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Lactones; Myocardial Infarction; Naproxen; Odds Ratio; Risk; Risk Assessment; Stroke; Sulfones	2006
Characterizing new users of NSAIDs before and after rofecoxib withdrawal. British journal of clinical pharmacology, 2007, Volume: 63, Issue:4 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Case-Control Studies; Cyclooxygenase 2 Inhibitors; Drug Approval; Female; Humans; Lactones; Male; Risk Factors; Sulfones; Time Factors	2007
Trying times for painkiller choices. Vioxx, Bextra, and Celebrex can increase the risk for heart attack and other cardiovascular problems. So can the old standbys, like ibuprofen and acetaminophen. Harvard heart letter : from Harvard Medical School, 2006, Volume: 17, Issue:2 Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Gastrointestinal Diseases; Isoxazoles; Lactones; Pyrazoles; Risk Assessment; Sulfonamides; Sulfones	2006
Cyclooxygenase inhibition and adverse remodeling during healing after myocardial infarction. Circulation, 2007, Jan-23, Volume: 115, Issue:3 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Humans; Isoxazoles; Lactones; Myocardial Infarction; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Risk Factors; Sulfonamides; Sulfones; Ventricular Remodeling	2007
Cardiac risks with COX-2 inhibitors. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2007, Feb-13, Volume: 176, Issue:4 Topics: Age Factors; Aged; Aged, 80 and over; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lactones; Male; Osteoarthritis; Risk Factors; Sulfones; Time Factors	2007
Coxibs: can this class of drugs survive? Vascular health and risk management, 2005, Volume: 1, Issue:1 Topics: Arthritis; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Etoricoxib; Evidence-Based Medicine; Half-Life; Humans; Isoxazoles; Lactones; Patient Selection; Pyrazoles; Pyridines; Sulfonamides; Sulfones	2005
Channelling of COX-2 inhibitors to patients at higher gastrointestinal risk but not at lower cardiovascular risk: the Cox2 inhibitors and tNSAIDs description of users (CADEUS) study. Pharmacoepidemiology and drug safety, 2007, Volume: 16, Issue:8 Topics: Adult; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cohort Studies; Cyclooxygenase 2 Inhibitors; Female; France; Gastrointestinal Diseases; Health Surveys; Humans; Lactones; Logistic Models; Male; Middle Aged; Patient Selection; Pharmacoepidemiology; Practice Patterns, Physicians'; Prospective Studies; Pyrazoles; Risk Factors; Sex Factors; Sulfonamides; Sulfones	2007
Man on a mission. Nature, 2007, May-31, Volume: 447, Issue:7144 Topics: Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus; History, 21st Century; Humans; Lactones; Quinolines; Rosiglitazone; Sulfones; Thiazolidinediones	2007
A proposed fairer method for conducting rofecoxib trials. Medical hypotheses, 2007, Volume: 69, Issue:6 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Ethics, Medical; Humans; Lactones; Models, Theoretical; Myocardial Infarction; Research Design; Sulfones	2007
Keeping science on top in drug evaluation. The New England journal of medicine, 2007, Aug-16, Volume: 357, Issue:7 Topics: Advisory Committees; Cardiovascular Diseases; Conflict of Interest; Cyclooxygenase Inhibitors; Dexfenfluramine; Drug Approval; Drug Evaluation; Drug Industry; Etoricoxib; Humans; Hypoglycemic Agents; Lactones; Pyridines; Risk; Rosiglitazone; Sulfones; Thiazolidinediones; United States; United States Food and Drug Administration	2007
Large-scale stopping and switching treatment with COX-2 inhibitors after the rofecoxib withdrawal. Pharmacoepidemiology and drug safety, 2008, Volume: 17, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cohort Studies; Cyclooxygenase 2 Inhibitors; Databases, Factual; Drug and Narcotic Control; Drug Prescriptions; Drug Therapy, Combination; Drug Utilization Review; Female; Gastrointestinal Diseases; Humans; Lactones; Male; Middle Aged; Practice Patterns, Physicians'; Proton Pump Inhibitors; Sulfones	2008
Merck's Careful Study of Vioxx. The American journal of cardiology, 2008, Apr-01, Volume: 101, Issue:7 Topics: Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Humans; Lactones; Sulfones; Treatment Outcome	2008
Rofecoxib (Vioxx): a year in review. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2001, Apr-03, Volume: 164, Issue:7 Topics: Adverse Drug Reaction Reporting Systems; Canada; Cardiovascular Diseases; Enzyme Inhibitors; Humans; Kidney Diseases; Lactones; Pain; Risk Factors; Sulfones	2001
Celecoxib-- the debate ranges on. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2001, Volume: 91, Issue:6 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Humans; Insurance Coverage; Lactones; Practice Guidelines as Topic; Pyrazoles; Rheumatic Diseases; Safety; Sulfonamides; Sulfones	2001
Pain relief at a price. A blow to the heart? U.S. news & world report, 2001, Sep-03, Volume: 131, Issue:8 Topics: Arthritis; Cardiovascular Diseases; Celecoxib; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Humans; Lactones; Pain; Pyrazoles; Risk; Sulfonamides; Sulfones	2001
Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). The American journal of cardiology, 2002, Jan-15, Volume: 89, Issue:2 Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Cardiovascular Diseases; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diclofenac; Female; Humans; Ibuprofen; Incidence; Lactones; Male; Middle Aged; Nabumetone; Osteoarthritis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk; Sulfones; Thrombosis; Treatment Outcome	2002